Nuevolution to present at three investor conferences in September 2017

Stockholm, 11 September 2017 -- Nuevolution AB (publ) (NUE.ST), a leading small-molecule drug-discovery biotech company, today announced that it will be presenting at three investor conferences in the US, Sweden and Denmark in September.

First, the company will present at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference will take place on 11-12 September 2017 at the Lotte New York Palace Hotel in New York City.

Henrik D. Simonsen, CFO of Nuevolution AB (publ), will provide an overview of the Company’s business during the live presentation on 12 September 2017, at 17:30-17:55 EDT (23:30-23:55 CEST). Mr. Simonsen and Ton Berkien, CBO, will be available to participate in one-on-one meetings with investors.

The presentation will be webcast live. To access the webcast, please visit or go to the investor relations section of Nuevolution’s website. The webcast replay will remain available for 90 days following the live presentation.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link ( to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

In addition, any investors attending the conference that wish to meet with Nuevolution’s management for a one-on-one meeting can also contact Henrik D. Simonsen at or Andrew Gibson at

Second, at Dansk Aktionærforening’s InvestorDagen in Copenhagen, Mr. Henrik D. Simonsen will provide an overview of the company’s business on Tuesday 19 September 2017, at 11:40-12:10 CEST. A few days after the event, a replay of the presentation can be found on

Third, at Aktiespararna’s Aktiedagen in Malmoe, Alex Haahr Gouliaev, the company’s CEO, will provide an overview of the Company’s business during the live presentation on Wednesday 27 September 2017, at 10:15-10:45 CEST. This event is webcast on A few days after the event, a replay of this event will be available on at

For more information, please contact:

Henrik D. Simonsen, CFO

Nuevolution AB (publ)

Phone: +45 3913 0947


Andrew Gibson (Investor Relations)


Phone: +1 (646) 653-7719


Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small-molecule drug-discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication, through the agency of the contact persons set out above, on Monday 11 September 2017 at 8:30 CEST.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on:


About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links